Bio-Rad collaborated with an experienced partner to extend their product portfolio of validated gene expression qPCR assays for human long non-coding RNAs (lncRNAs). To ensure the success of this project, they relied on a trusted adviser that they knew would deliver. That partner was Biogazelle.

After suffering an abrupt service termination by their previous PCR provider, DNAlytics needed a trustworthy and experienced partner to perform the wet lab work for their diagnostic kit for arthritis patients. Their search criteria were strict, and only Biogazelle could offer everything they needed. Biogazelle provided a seamless transition for DNAlytics that allowed them to return their focus to business-critical activities.

GeNeuro has developed the antibody GNbAC1 as therapeutic in Multiple Sclerosis (MS), and a Phase IIb study is currently running. geNeuro wanted Biogazelle to develop an RNA-based test to stratify MS patients that will likely benefit from a treatment with GNbAC1.

The Belgian biotech company argenx is currently running a clinical trial of ARGX-110, a first-in-class SIMPLE antibody targeting CD70, an immune checkpoint target involved in hematological malignancies, solid tumors and severe autoimmune diseases.